{"id":"NCT02869438","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-09","primaryCompletion":"2018-08-01","completion":"2018-08-01","firstPosted":"2016-08-17","resultsPosted":"2019-10-07","lastUpdate":"2019-10-29"},"enrollment":233,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"OTHER"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Benralizumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab arm","type":"EXPERIMENTAL"},{"label":"Placebo arm","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.","primaryOutcome":{"measure":"Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1","timeFrame":"From first IP dose to Day 84","effectByArm":[{"arm":"Benra 30 mg","deltaMin":0.21,"sd":0.335},{"arm":"Placebo","deltaMin":0.132,"sd":0.316}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0707"},{"comp":"OG000 vs OG001","p":"0.7747"},{"comp":"OG000 vs OG001","p":"0.0969"},{"comp":"OG000 vs OG001","p":"0.1558"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States","Chile","Germany","Hungary","Philippines","South Korea"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4080&filename=d3250c00038-csp-v1_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4080&filename=d3250c00038-sap-ed-2_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":118},"commonTop":["Asthma","Nasopharyngitis","Upper respiratory tract infection","Bronchitis"]}}